RESEARCH TRIANGLE PARK, N.C. - Wednesday, November 28th 2012
Quintiles Founder Dennis Gillings, CBE, has received the SCRIP Lifetime Achievement Award and the company he started has been named “CRO of the Year” at the 2012 SCRIP Awards in London.
The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 16 life sciences experts. The 8th annual awards ceremony, held on November 28th at The Lancaster hotel in London, was attended by more than 500 industry leaders from around the world.
Being named CRO of the Year by SCRIP is a prestigious honor for Quintiles, the world’s leading provider of biopharmaceutical services. It is one of the most competitive awards bestowed by SCRIP, and Quintiles has received it three times in the past four years.
Likewise, Dennis Gillings’ lifetime achievement award is equally celebrated. Mike Ward Chief Content Officer for Datamonitor Healthcare and Scrip Intelligence said, “Scrip’s Lifetime Achievement Award is reserved for an individual who has made an outstanding contribution to the pharmaceutical/biotech industry. In founding Quintiles, Dennis Gillings made an indelible impact on drug development by pioneering the Clinical Research Organization industry, revolutionizing the field to the extent that clinical trials expertise now rests with these companies. The CRO sector is still fast growing and plays a crucial role in drug development.”
“I am honored to receive this award,” said Dr. Gillings. “It is humbling to be recognized by this prestigious panel, and I share this with Quintiles’ employees, past and present, around the world who make our company what it is today. During these past three decades, many diseases have gone from being life threatening to manageable thanks to the work we have done with our biopharmaceutical customers.
“As we look ahead, I believe we on are on the cusp of many new discoveries which will further transform healthcare. It is my goal to ensure that Quintiles can help enable that innovation to make a difference to patients around the world.”
Dr. Gillings has invested his 40-plus year career working to improve health around the world, beginning in 1971 as a professor of biostatistics at the University of North Carolina. In April 2012, he stepped away from the day-to-day operations of Quintiles and he continues to serve as executive chairman. Today, Quintiles is the largest global provider of services to the pharmaceutical and biotechnology industry.
Under Dr. Gillings’ leadership, Quintiles helped develop or commercialize all of 2011’s top 50 best-selling products or compounds, top 30 best-selling cardiovascular products or compounds, and top 40 best-selling oncology products or compounds.
Other recent awards for excellence received by Quintiles include:
Ranked in top 25 in the World’s Best Multinational Workplaceslist from the Great Place to Work® Institute in 2011 and 2012.
Placed sixth in the InformationWeek 500 technology innovatorsrankings for Quintiles' collaboration with Eli Lilly on an IT-enabled project to eliminate inefficiencies and use "big data" to drive better drug development decisions.
Recognized by the Great Place to Work Institute in 2012 as one of the top workplaces in Canada, Germany, Ireland, Italy, Mexico, Scotland, Spain, United Kingdom and Europe.
Named Best CRO in the Vaccine Industry Excellence (ViE) Awards2012.
Named to Computerworld magazine’s 100 Best Places to Work in ITlist for a third time.
About Quintiles
Quintiles is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Media Relations:
Phil Bridges,
+ 1-919-998-1653 (office)
phil.bridges@quintiles.com
Investor Relations:
Greg Connors,
+1-919-998-2000
invest@quintiles.com
No comments:
Post a Comment